Powder: -20°C for 3 years | In solvent: -80°C for 1 year
MCB-613 是类固醇受体共激活因子 (SRC) 小分子“刺激物” (SMS),超刺激 SRCs 的转录活性。它促进 SRC 与其他共激活因子发生相互作用,并显著诱导 ER 应激与活性氧的产生相结合。它是一种 SMS,能够过度刺激 SRC 致癌程序,靶向癌基因用作抗癌药物。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 301 | 现货 | ||
2 mg | ¥ 458 | 现货 | ||
5 mg | ¥ 913 | 现货 | ||
10 mg | ¥ 1,490 | 现货 | ||
25 mg | ¥ 2,730 | 现货 | ||
50 mg | ¥ 4,120 | 现货 | ||
100 mg | ¥ 5,890 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 975 | 现货 |
产品描述 | MCB-613 is an effective steroid receptor coactivator (SRC) stimulator. |
体外活性 | MCB-613 selectively and reversibly binds to the RID of SRC-3, and selectively kills cancer cells including MCF-7 (breast), PC-3 (prostate), H1299 (lung), and HepG2 (liver) cells, without toxicity to mouse primary hepatocytes and mouse embryonic fibroblasts (MEFs). MCB-613 also increases SRCs' interactions with other coactivators and markedly induces ER stress coupled to the generation of reactive oxygen species (ROS). [1] |
体内活性 | In an MCF-7 breast cancer mouse xenograft model, MCB-613 (20 mg/kg, i.p.) significantly and dramatically inhibits the growth of the tumor while causing no obvious animal toxicity and body weight less. [1] |
激酶实验 | Luciferase assays: After various compound treatments, cells are lysed in luciferase lysis buffer and assayed for luciferase activity using the ONE-Glo luciferase assay system. All luciferase activities are normalized to protein concentration determined by Bradford assay. |
细胞实验 | Cells are seeded in 96-well plates and allowed to reach 60% to 70% confluence. After indicated compound treatments, relative numbers of viable cells are measured by MTS assay using the Cell Titer 96 Aqueous One Solution Cell Proliferation Assay.(Only for Reference) |
别名 | MCB 613 |
分子量 | 304.39 |
分子式 | C20H20N2O |
CAS No. | 1162656-22-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: < 1 mg/mL (insoluble or slightly soluble)
Ethanol: 56 mg/mL (184 mM)
DMSO: 56 mg/mL (184 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
Ethanol / DMSO | 1 mM | 3.2853 mL | 16.4263 mL | 32.8526 mL | 82.1315 mL |
5 mM | 0.6571 mL | 3.2853 mL | 6.5705 mL | 16.4263 mL | |
10 mM | 0.3285 mL | 1.6426 mL | 3.2853 mL | 8.2131 mL | |
20 mM | 0.1643 mL | 0.8213 mL | 1.6426 mL | 4.1066 mL | |
50 mM | 0.0657 mL | 0.3285 mL | 0.6571 mL | 1.6426 mL | |
100 mM | 0.0329 mL | 0.1643 mL | 0.3285 mL | 0.8213 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
MCB-613 1162656-22-5 Angiogenesis Tyrosine Kinase/Adaptors Src inhibit Inhibitor MCB613 MCB 613 inhibitor